Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO6870810 and Venetoclax in R/R DLBCL and HGBL
NCT03255096Phase 1Completed
- Sponsor
- Roche
- Start
- Aug 2017
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of RO-6870810 in diffuse large B-cell lymphoma (DLBCL) and high grade B-cell lymphoma (HGBCL) (2 arms), sponsored by Roche. Primary endpoints: Percentage of Participants With Dose-Limiting Toxicities, Percentage of Participants With Adverse Events up to 36 months and 3 more. Started Aug 2017; status: completed.
02
Drugs
RO-6870810
03
Conditions
diffuse large B-cell lymphoma (DLBCL)high grade B-cell lymphoma (HGBCL)
Beyond the preview
Go deeper on NCT03255096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03255096.